Singapore markets closed
Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,719.71 -2,094.22 (-3.33%) CMC Crypto 200
1,259.14 -98.87 (-7.28%)
Vaxcyte, Inc. (5VA.MU)
Munich - Munich Delayed price. Currency in EUR
Add to watchlist
At close: 08:03AM CEST
| Previous close | 62.50 |
| Open | 61.00 |
| Bid | 60.50 x N/A |
| Ask | 61.00 x N/A |
| Day's range | 61.00 - 61.00 |
| 52-week range | 41.40 - 74.50 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 6.636B |
| Beta (5Y monthly) | 0.94 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.99 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview
Consistent with Analyst Projections Amidst Strategic Advancements
GlobeNewswireVaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen
GuruFocus.comInsider Sale at Vaxcyte Inc: COO Jim Wassil Sells 3,000 Shares
On May 1, 2024, Jim Wassil, the Chief Operating Officer of Vaxcyte Inc (NASDAQ:PCVX), sold 3,000 shares of the company.
© 2024 Yahoo. All rights reserved.